If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.16    -0.0105 (-6.16%)
Bid:
0.15
Ask:
0.17
Spread: 0.02 (13.333%)
Market Cap: £2.11m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Final Results

23 Jun 2005 14:42

AZURE HOLDINGS PLC PRELIMINARY ANNOUNCEMENT OF RESULTS YEAR ENDED 31 DECEMBER 2004 Chairman's StatementI am pleased to present my report for the year ended 31 December 2004.Your Company is still seeking a suitable merger target. During the period, theCompany entered into discussions with an acquisition target but the board couldnot agree commercial terms and talks were terminated.Your board is pursuing other acquisition targets which, owing to their size,may result in a reverse takeover.In the meantime, the directors have agreed not to draw their salaries and arefocused on keeping overheads to a minimum.Nicolas GreenstoneChairman23 June 2005Profit and loss accountfor the year ended 31 December 2004 Year ended Year ended 31 31 December December 2004 2003 ‚£'000 ‚£'000 Administrative expenses (345) (86) Profit on disposal of investments - 10 Operating loss (345) (76) Loss on disposal of subsidiary undertakings - (74) Loss on ordinary activities before taxation (345) (150) Taxation - - Loss on ordinary activities after taxation (345) (150) Loss per share (0.86p) (4.14p) Fully diluted loss per share (0.86p) (4.14p) The Group has no recognised gains and losses other than the loss for the year.Balance sheetas at 31 December 2004 2004 2003 ‚£'000 ‚£'000 Current assets Debtors 7 7 Cash at bank and in hand 14 119 21 126 Creditors: amounts falling due within one year (90) (59) Net current (liabilities)/assets (69) 67 Total assets less current liabilities (69) 67 Capital and reserves Called up share capital 5,475 5,304 Share premium account 10,279 10,241 Profit and loss account (15,823) (15,478) Equity shareholders' (deficit)/funds (69) 67 Cash flow statementfor the year ended 31 December 2004 2004 2003 ‚£'000 ‚£'000 Cash outflow from operating activities (225) (76) Financing Issue of equity shares 120 195 (Decrease)/increase in cash in the year (105) 119 Notes to the preliminary announcementfor the year ended 31 December 2004 1. Basis of preparation The financial information in this announcement does not constitute statutoryfinancial statements as defined in Section 240 of the Companies Act 1985. Theinformation relating to the year ended 31 December 2003 is an extract from thestatutory accounts for that year, which have been delivered to the Registrar ofCompanies. The auditors' report on those accounts was unqualified and did notcontain any statement under section 237(2) or (3) of the Companies Act 1985.The auditors have indicated that they will issue an unqualified report on thestatutory financial statements for the year ended 31 December 2004. Copies ofthe Company's Report and Financial Statements will be sent to shareholdersshortly and will be available at the registered office of the Company: OneGreat Cumberland Place, London W1H 7AL . 2. Going concern The financial statements have been prepared on a going concern basis inaccordance with applicable United Kingdom Accounting Standards.The directors have adopted this basis as they consider that the company hassufficient working capital to meet its obligations as they fall due.Chiddingfold Investments Limited, has agreed to fund the company's workingcapital requirements for a period until 30 June 2006, to the extent that suchcosts are not covered by other fund raisings or reverse acquisitiontransactions.During the year the Company made losses of ‚£345,000 and had net liabilities at31 December 2004 of ‚£69,000.The directors continue to actively seek suitable targets for a reverseacquisition.The directors have therefore prepared the financial statements on the goingconcern basis. The financial statements do not include any adjustments thatmight arise if this basis was inappropriate. 3. Basis of consolidation The consolidated financial statements include the financial statements of theCompany and have been prepared using both merger accounting principles andacquisition accounting principles.The Company has not presented its own profit and loss account as permitted bySection 230(3) of the Companies Act 1985. The Company's loss for the financialyear was ‚£345,000.4. Loss per shareLoss per share are calculated on a net basis using the loss on ordinaryactivities and the weighted average number of shares detailed below.In calculating fully diluted loss per share, the weighted average number ofshares is adjusted for the effect of dilutive share options issued under Groupshare option schemes. 2004 2003 ‚£'000 ‚£'000 Basic and diluted losses attributable to ordinary (345) (150)shareholders Number Number Weighted average number of ordinary shares 39,767,965 3,625,812 Dilutive share options - - Adjusted weighted average number of ordinary shares 39,767,965 3,625,812 Loss per share (0.86p) (4.14p) Fully diluted loss per share (0.86p) (4.14p) 5. Reconciliation of operating loss to net cash outflow from operating activities 2004 2003 ‚£'000 ‚£'000 Operating loss (345) (76) Decrease in debtors - 48 Increase/(decrease) in creditors 31 (48) Creditor settled via issue of shares 89 - Net cash outflow from operating activities (225) (76) 6. Reserves Share Profit and Total premium loss account account ‚£'000 ‚£'000 ‚£'000 At 1 January 2004 10,241 (15,478) (5,237) Loss for the year - (345) (345) Issue of shares 38 - 38 At 31 December 2004 10,279 (15,823) (5,544) 7. Taxation Factors affecting taxation:The tax charge for the year does not equate to the loss before tax at thestandard rate of corporation tax in the United Kingdom (30%). The differencesare explained below: 2004 2003 ‚£'000 ‚£'000 Loss on ordinary activities before taxation (345) (150) Loss on ordinary activities multiplied by the (104) (45)standard rate of corporation tax in the United Kingdom of 30% (2003: 30%) Effect of non-deductible expenses and addition to 104 45tax losses - - At 31 December 2004, the company had accumulated tax losses of ‚£817,627 arisingform management expenses and ‚£1,476,749 of capital losses. 8. Dividends The Directors are not proposing the payment of a dividend in respect of theyear ended 31 December, 2004.ENDAZURE HOLDINGS PLC
Date   Source Headline
26th May 20168:00 amRNSPosting of Annual Report & Notice of AGM
19th May 201611:00 amRNSFinal Results
19th May 20167:00 amRNSValiSeek Clinical Development Update
18th May 20164:45 pmRNSConversion of Loan Note, issue of warrant & equity
29th Apr 20167:00 amRNSNotification of US Patent Grant for VAL401
26th Apr 201612:07 pmRNSIssue of Equity
22nd Apr 201610:01 amRNSValiRx to exhibit at the UK Investor Show
19th Apr 20163:32 pmRNSIssue of Equity - conversion of loan note
18th Apr 20165:00 pmRNSIssue of Equity - conversion of loan note
1st Apr 20163:10 pmRNSConversion of Loan Note, issue of warrant & equity
31st Mar 20167:00 amRNSValiRx to exhibit and present at the AACR
21st Mar 20167:00 amRNSConvertible Loan Facility of up to £4.0 million
17th Mar 20167:00 amRNSValiRx engages US investor relations firm
17th Feb 20161:00 pmRNSPlacing to raise £0.5 million
16th Feb 20167:00 amRNSVAL201 Clinical Trial Update
9th Feb 20167:00 amRNSQuarterly Update on Clinical Progress
11th Dec 20159:30 amRNSValiRx to present at Shares Investor Meeting
19th Nov 201510:45 amRNSClinical Phase Development Update
5th Nov 20157:00 amRNSValiRx establishes US office in Boston, MA
27th Oct 20157:00 amRNSCollaboration Agreement
1st Oct 20157:00 amRNSNew Japanese Patent Grant
17th Sep 201512:15 pmRNSHalf Yearly Report
16th Sep 20157:00 amRNSSubscription and Equity Swap
6th Aug 20157:00 amRNSCollaboration and Research Studentship Agreement
21st Jul 20157:00 amRNSVAL201 Clinical Trial Update
16th Jul 20157:00 amRNSValiSeek Clinical Development Update
29th Jun 20157:00 amRNSGrant of options
25th Jun 20157:00 amRNSUPDATE on VAL201 Clinical Trial
3rd Jun 20157:00 amRNSChange of Adviser
27th May 201511:22 amRNSStmnt re Share Price Movement
15th May 20152:45 pmRNSResult of AGM and Capital Reorganisation
14th May 20153:50 pmRNSNotification of US Patent Grant Allowance reVAL401
14th May 20157:00 amRNSValiSeek Development Update
7th May 20157:00 amRNSRe Contract
30th Apr 20157:00 amRNSValiRX to attend 2015 BIO International Convention
22nd Apr 20157:00 amRNSNotice of AGM and Proposed Capital Reorganisation
16th Apr 20157:00 amRNSFinal Results
17th Mar 20157:00 amRNSIssue of equity to Cancer Research Technology Ltd
6th Mar 20157:00 amRNSPlacing to raise GBP800,000
26th Feb 20157:00 amRNSNew Endometriosis Patent Grant
24th Feb 20157:00 amRNSSuccessful 1st Results from VAL201 Clinical Trial
11th Feb 20157:00 amRNSNew European Patent Grant
5th Feb 20157:00 amRNSAcquisition
15th Jan 20157:00 amRNSClinical Trial and Development Update
18th Dec 20147:00 amRNSIssue of Equity
4th Dec 20147:00 amRNSValiSeek Scientific Update
26th Nov 20147:00 amRNSRe: Progress with Trial Recruitment and Testing
13th Nov 20147:00 amRNSCollaboration Agreement
7th Nov 201410:23 amRNSHolding(s) in Company
3rd Nov 201411:00 amRNSApproved Clinical Trial Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.